Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial

Supportive Care in Cancer

Volumn 20, Issue 12, 2012, Pages 3355-3364

  Shimozuma, Kojiro ^a   Ohashi, Yasuo ^b   Takeuchi, Ayano ^b   Aranishi, Toshihiko ^b   Morita, Satoshi ^c   Kuroi, Katsumasa ^d   Ohsumi, Shozo ^e   Makino, Haruhiko ^f   Katsumata, Noriyuki ^g   Kuranami, Masaru ^h   Suemasu, Kimito ^i,j   Watanabe, Toru ^k   Hausheer, Frederick H ^l  

^a RITSUMEIKAN UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^f NIIGATA CITY GENERAL HOSPITAL   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL   (Japan)

^h KITASATO UNIVERSITY HOSPITAL   (Japan)

ⁱ SAITAMA CANCER CENTER   (Japan)

^j Arche Clinic   (Japan)

^k Hamamatsu Oncology Center   (Japan)

^l BioNumerik Pharmaceuticals Inc   (United States)

more..

Author keywords

Adjuvant chemotherapy; Chemotherapy induced peripheral neuropathy; Health related quality of life; Patient Neurotoxicity Questionnaire

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NATIONAL CANCER INSTITUTE COMMON TOXICITY CRITERIA; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PATIENT NEUROTOXICITY QUESTIONNAIRE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PACLITAXEL; PARESTHESIA; PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; QUESTIONNAIRES; TAXOIDS;

EID: 84868480398     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1492-x     Document Type: Conference Paper

References (27)

1. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK (2007) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 4:CD004421
2. Sparano JA,WangM,Martino S et al (2008)Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671
3. Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125:47-58
4. Winer EP, Berry DA, Woolf S et al (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22:2061-2068
5. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004-1014
6. Hilkens PH, ven den Bent MJ (1997) Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 2:350-361
7. Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633-1642
8. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP (2008) Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 66:218-228
9. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507-1515
10. Harvey V, Mouridsen H, Semiglazov V et al (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24:4963-4970
11. Litwin MS, Lubeck DP, Henning JM, Carroll PR (1998) Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 159:1988-1992
12. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22:3485-3490
13. Basch E, Iasonos A, McDonough T et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903-909
14. Petersen MA, Larsen H, Pedersen L, Sonne N, Groenvold M (2006) Assessing health-related quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer 42:1159-1166
15. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739-744
16. Postma TJ, Heimans JJ (2000) Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 11:509-513
17. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapyinduced peripheral neuropathy. Semin Oncol 33:15-49
18. Sloan JA, Berk L, Roscoe J et al (2007) Integrating patientreported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 25:5070-5077
19. Kuroi K, Shimozuma K, Ohashi Yet al (2009) Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer 17:1071-1080
20. Kuroi K, Shimozuma K, Ohashi Y et al (2008) A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer. Jpn J Clin Oncol 38:748-754
21. Shimozuma K, Ohashi Y, Takeuchi A et al (2009) Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17(12):1483-1491
22. Cella DF, Tulsky DS, Gray G et al (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11:570-579
23. Fumimoto H, Kobayashi K, Chang CH et al (2001) Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese. Qual Life Res 10:701-709
24. Calhoun EA, Welshman EE, Chang CH et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741-748
25. Huang HQ, Brady MF, Cella D, Fleming G (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxelinduced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17:387-393
26. Ohsumi S, Sunada Y (2004) Techniques for the neurological examination of taxane-induced neuropathy. Breast Cancer 11:86-91
27. Jones SE, Erban J, Overmoyer B et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551